Hangzhou Thinheal Pharma-tech

Hangzhou Thinheal Pharma-tech is a clinical-stage biotechnology company based in Hangzhou, China, specializing in the development of innovative and improved small molecule drugs. The company focuses on the therapeutic areas of anesthesia, analgesia, and the central nervous system (CNS), utilizing proprietary long-acting drug delivery technologies. Its lead program, XH-101, is a long-acting local anesthetic currently in Phase 2 clinical trials for the management of postoperative pain. Thinheal's pipeline also features XH-102, a novel sedative-hypnotic agent in early-stage clinical development. By leveraging advanced formulation techniques, the company aims to improve the safety and efficacy profiles of existing treatments and address significant unmet medical needs in perioperative care. Thinheal is supported by prominent regional investors and maintains a strong focus on the Chinese domestic market while exploring global opportunities.